Transcript
Ann Berry (0:01)
Tonight's State of the Union address will likely shine a light on nuclear power. So we take a look at one star stock in alternative energy. The latest at Constellation, Henry Schein, FactSet, AMD and Warner Brothers. Our sprint through the earnings deals and merger drama all moving the market today. And barely perceptible product differences. Sprints for distribution, headline domination and now aggressive price cuts. No, not the news cycle for the major LLMs, but the latest in the eerily similar war of the GLP1s. We break it all down for Tuesday, February 24th. It's Brew Markets Daily and I'm Ann Berry. More market details to come. But first, a major player drops a product and all its investors cheer. Then a competitor goes incrementally better and panic sets in. Then major player one drops an even better update and investors take a victory lap. And then a competitor pops up, ups the ante and the roller coaster starts all over again. So is this OpenAI versus Google's Gemini versus anthropic? Well, on any given day it could be. But today it's the latest in the GLP1 wars and they're not too dissimilar with The Novo Nordisk versus Eli Lilly versus Pfizer. News Roundabout. Well, just yesterday Novo's share price dropped 15% to a four year low. And that was in reaction to disappointing phase three trial results for its next gener obesity drug CAG sema. To get all these syllables out, well, investors were underwhelmed by the drug which showed 20% weight loss results just below Eli Lilly's Zeppelin at 23.6%. So these are not vast, vast differences. Well, today Novo announced plans to slash the monthly list prices of its popular obesity and diabetes drugs in the United States by up to 50% starting next year. The obesity injection Wegovy and its new pill counterpart, plus Novo's diabetes treatments, the Ozempic shot and the oral drug Rebelsus will have the new lower list price of $675 per month starting on January 1, 2027. Well, that's a significant drop from the $1,027 to $13.50 per month the drugs are currently listed for. The price cuts target insured patients whose out of pocket costs are linked to list prices. So that would include folks with high deductible health plans or co insurance benef lines. And its timing coincides with new lower Medicare prices going into effect for Novo's obesity and diabetes drugs next year under the inflation Reduction Act. Well, the move could help Novo compete better with Eli Lilly which has now outrun Novo to hold the majority share of the blockbuster GLP1 market. Despite Novo's first mover status, Lilly's more effective drugs and earlier push into the direct to consumer space for distribution have allowed it to take the lead and all without significantly lowering the US list prices of its medicine reasons. So this is just my one person's view. If as a company you've exhausted the ways to compete outside of price, you've exhausted the ability to get ahead in product benefits or in meeting customers where they are, or in marketing and brand awareness. And if you find yourself in the spot where dropping prices is now all you've got left to fight with, then you better be sure you're going to win. Because once those price cuts are there, they tend not to be reversed and often the whole sector loses if demand doesn't down slow, suddenly expand. Which is why I think Novo is down today by more than 2%. Eli Lilly also ticked down over the course today while they think about their pricing reaction. So this is not going to stop anytime soon. It feels to me like this is just the start of a new chapter with pricing at the core of it. We still need to hear from Pfizer what they're going to do next, so we're going to keep on watching. Well, coming up, we break down one star among energy sector stocks and that's Constellation, the non fossil fuel player, plus Henry Shine of FactSet, some nuggets less covered names, plus Paramount's new salvo in the battle for Warner Brothers. But first, a word from our sponsor, Charles Schwab. Trading at Schwab is powered by Ameritrade, bringing you an expanding library of education with even more ways to sharpen your trading skills. Access new online courses, insightful webcasts, articles, engaging videos and more, all curated just for traders.
